COO
The Cooper Companies, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$69.59
−1.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.2B | 4.1B | 3.9B | 3.6B | 3.3B |
| Cost of Revenue | 1.5B | 1.6B | 1.3B | 1.2B | 1.2B |
| Gross Profit | 2.7B | 2.5B | 2.6B | 2.4B | 2.1B |
| Operating Expenses | |||||
| R&D Expense | 172.8M | 172.2M | 155.1M | 137.4M | 110.3M |
| SG&A Expense | 1.9B | 1.6B | 1.5B | 1.5B | 1.3B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 145.6M | — | 201.2M | 186.2M | 179.5M |
| Total Operating Expenses | 2.2B | 1.8B | 1.9B | 1.8B | 1.6B |
| Cost and Expenses | 3.7B | 3.4B | 3.2B | 3.1B | 2.8B |
| Operating Income (EBIT) | 497.9M | 682.9M | 705.7M | 533.1M | 507.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 93.1M | 100.0M | 114.3M | 105.3M | 57.3M |
| Net Interest Income | (93.1M) | (100.0M) | (114.3M) | (105.3M) | (57.3M) |
| Other Non-Op Income/Expense | (85.4M) | (116.4M) | (123.4M) | (120.2M) | (32.3M) |
| Non-Operating Income (excl Interest) | 16.7M | 52.5M | 9.1M | 14.9M | (25.0M) |
| EBT (Pre-Tax Income) | 412.5M | 566.5M | 582.3M | 412.9M | 475.3M |
| Income Tax Expense | 176.7M | 191.6M | 190.0M | 118.7M | 89.5M |
| Bottom Line | |||||
| Net Income | 235.8M | 374.9M | 392.3M | 294.2M | 385.8M |
| Earnings from Cont. Ops | 235.8M | 374.9M | 392.3M | 294.2M | 385.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 235.8M | 374.9M | 392.3M | 294.2M | 385.8M |
| Per Share | |||||
| Basic EPS | $1.18 | $1.88 | $1.97 | $1.49 | $1.96 |
| Diluted EPS | $1.18 | $1.87 | $1.96 | $1.48 | $1.94 |
| Revenue Per Share | $21.70 | $20.46 | $19.58 | $18.15 | $16.78 |
| Shares | |||||
| Basic Shares Outstanding | 195.0M | 200.0M | 198.9M | 198.0M | 197.2M |
| Diluted Shares Outstanding | 195.0M | 200.0M | 200.4M | 199.2M | 198.8M |
| Profitability Metrics | |||||
| EBITDA | 865.9M | 1.1B | 1.1B | 885.9M | 878.7M |
| D&A | 384.7M | 423.0M | 375.1M | 367.7M | 346.1M |
| EBIT | 481.2M | 630.4M | 696.6M | 518.2M | 532.6M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Apr 1, 2026